Navigation Links
Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients
Date:3/19/2008

nding the current product label into adult AML. Preliminary data has been accepted for presentation at ASCO this spring and a supplemental new drug application (sNDA) for clofarabine is expected to be filed in the second half of this year. It is possible that data from this study also could be considered for part of a new filing with EMEA.

Evoltra is currently indicated for the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients who have relapsed or are refractory to at least two prior regimens. The withdrawal of the European application of Evoltra in adult AML has no consequences for patients enrolled in current clinical trials or compassionate use programs.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

This press release contains forward-looking statements, including the expected results of the data generated from clofarabine clinical trials, the presentation and use of this data to support regulatory filings, and t
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... According to new market research ... Types (Colocation, Enterprise, Telecom), by Design Types (Electrical, ... 2, Tier 3, Tier 4) - Global Forecast ... the Data Center Construction Market into various segments ... This research report also identifies the factors driving ...
(Date:10/25/2014)... 2014 SonaCare Medical, LLC, leader ... technology, announced that its Board of Directors has ... Officer, President and member of the Board effective ... take-on expanded responsibilities within the company, including further ... overseeing commercialization, manufacturing and finance. , Dr. ...
(Date:10/25/2014)... Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" or "RegeneRx") today ... on Thymosins in Health and Disease in ... beta 4 (TB4) linked with rhodamine (a fluorescent tracer ... rodent model of stroke, it was visualized outside of ... tissue of the brain).   The leakage of TB4 in ...
(Date:10/22/2014)... -- Research and Markets has announced ... Market (Product types, Application, Technology, End User and ... Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and ... offering. This new report titled, ... and Geography) Global Size, Industry Analysis, Trends, Opportunities, ...
Breaking Biology Technology:Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3
... recent report that probably went unnoticed outside the academic ... released figures that show why the rest of us ... for scientific research. The numbers demonstrate that investment in ... it's about creating jobs for the 21st century economy. ...
... Technical College would like to see more women going into ... women in IT careers has declined from a high of 41 ... And at MATC, enrollment of women in IT programs has dropped ... IT Expo at the college on Wednesday was Patricia Prime, ...
... . and Imaxio S.A. (Saint-Beauzire, France) have ... manufacture and sell OverExpress bacterial cells for ... retain the right to license the use of OverExpress ... cells to commercial licensees. No license will be required ...
Cached Biology Technology:Tapping hidden assets: Wisconsin researchers who can create jobs 2Tapping hidden assets: Wisconsin researchers who can create jobs 3Tapping hidden assets: Wisconsin researchers who can create jobs 4MATC seeks to turn around falling tech enrollment among women 2Lucigen Corp. enters global licensing agreement 2
(Date:10/15/2014)... , Oct. 15, 2014 Sandata Technologies, ... home and community-based care, today announced it released ... Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™)  for ... a home health company founded in 1996 and ... . The study details the ...
(Date:10/15/2014)... linked increased resistance to bacterial pneumonia in female mice ... estrogen. , Females are naturally more resistant to respiratory ... has shown that increased resistance to bacterial pneumonia in ... synthase 3 (NOS3). They also show that this enzyme ... sex hormone estrogen. , The team, lead by Professor ...
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to ... the development of skin cancers by turning on an ... skin cells. , Previously considered protective, SIRT6 is part ... help regulate genomic stability and prevent some of the ... damage, which can lead to cancer. This study, in ...
Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
... Mass. Joshua Kritzer, assistant professor in the School ... University, has been awarded one of 33 NIH Director,s ... awarded by the National Institutes of Health. The ... to support unusually creative new investigators with highly innovative ...
... -- November 12, 2010 --Canadian biologist Chris Wood was ... Science. The Award was presented by Dr. Philip Campbell, ... for Graduate Studies annual meeting in Toronto earlier this ... Royal Society of Canada, is a professor in the ...
... Powdery mildew is a fungus that infects both crop and ... cause immense crop loss. Despite decades of intense research, little ... to invade the host,s epidermal cells. A European research group ... of Zurich, now published a study in Science ...
Cached Biology News:Tufts University chemist earns prestigious award for promising research on drug development 2Nature honors outstanding faculty mentor 2Fertility or powdery mildew resistance? 2Fertility or powdery mildew resistance? 3
Whole blood is collected from mice (Swiss Webster, 8-10 weeks old,either sex) and processed within 45 minutes of collection. The complement is then filtered and pooled on ice, bottled and stored at -...
... incorporating the sophisticated DirectDrive architecture and ... Varian NMR System is undeniably the ... Varian NMR System features parallel controllers ... providing pulse sequence programming power with ...
... Anti-HMGN2/HMG-17 Immunogen : Recombinant ... pH7.4, 5mg/ml BSA, 0.15M NaCl, ... addition of glycerol to 30% ... immunoblot on acid extracts of ...
Luminometers...
Biology Products: